logo image
search icon
date background image

Jul 10, 2024

PARP Inhibitors Poised to Revolutionize Cancer Treatment- Market Research Report

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global PARP Inhibitors Market Size, Share & Trends Analysis Report By Product (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), Talazoparib (Talzenna), Veliparib, Other Pipeline Drugs), By Indication(Ovarian Cancer, Breast cancer, Prostate and Pancreatic Cancer)- Market Outlook And Industry Analysis 2031"


The Global PARP Inhibitors Market is valued at US$ 3,425.2 Mn in 2023, and it is expected to reach US$ 10,317.3 Mn by 2031, with a CAGR of 15.12% during the forecast period of 2024-2031.


Request Complete FREE Sample Report Click Here: https://www.insightaceanalytic.com/request-sample/1169


PARP inhibitors are crucial class of targeted cancer therapies that operate by inhibiting the enzyme poly (ADP-ribose) polymerase (PARP), essential for DNA repair processes. By blocking PARP activity, these drugs effectively target cancer cells with compromised DNA repair mechanisms, particularly those carrying mutations in genes like BRCA1 and BRCA2. These inhibitors have garnered approval for treating specific types of cancers, notably ovarian, fallopian tube, and peritoneal cancers, as well as HER2-negative breast cancers harboring BRCA mutations. They are effective in both early-stage and metastatic settings for breast cancer. Beyond these indications, ongoing clinical trials are exploring their potential in treating other cancer types such as prostate, pancreatic, lung, and brain tumors.


The primary PARP inhibitors currently available or in advanced stages of development include Olaparib (Lynparza), Rucaparib (Rubraca), Niraparib (Zejula), and Talazoparib (Talzenna). These medications are typically administered orally, either as tablets or capsules, and are generally taken once or twice daily. PARP inhibitors represent a significant advancement in cancer treatment due to their targeted mechanism, which selectively eradicates cancer cells while minimizing damage to healthy cells. This targeted approach marks a departure from traditional chemotherapy, potentially offering patients improved outcomes and reduced side effects compared to conventional treatments. As ongoing research continues to uncover additional applications and refine treatment protocols, PARP inhibitors hold promise in transforming the landscape of cancer therapy.


List of Prominent Players in the PARP Inhibitors Market:

  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • GSK plc.
  • Pfizer Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Artios Pharma
  • Genentech, Inc.
  • Karyopharm Therapeutics Inc.
  • Repare Therapeutics Inc
  • Jiangsu Hengrui Pharma Co., Ltd.
  • Bristol-Myers Squibb Co
  • AstraZeneca plc
  • Checkpoint Therapeutics, Inc.
  • Eisai Co., Ltd.
  • IMPACT Therapeutics
  • Kyowa Kirin Co., Ltd
  • SyntheX


Market Dynamics:



The incidence of cancer, including breast, ovarian, prostate, and pancreatic cancers, continues to rise globally, with nearly 20 million new cases reported in 2022. This surge is driving demand for effective treatments like PARP inhibitors, which are already approved for these cancers and show promise in new indications. The market for PARP inhibitors is expanding rapidly, supported by advancements in precision medicine and genetic testing that identify patients likely to benefit, such as those with BRCA mutations. Favorable regulatory environments and strategic collaborations between pharmaceutical and diagnostic companies further bolster their adoption, underscoring significant growth opportunities in oncology therapeutics.



The high development costs of PARP inhibitors pose a significant challenge, potentially limiting market entry and impacting pricing strategies. Intense competition among pharmaceutical companies may lead to market saturation, pricing pressures, and difficulties in product differentiation. Additionally, advancements in alternative cancer therapies threaten to divert attention and investment from further PARP inhibitor development.


Regional Trends:

North America leads the PARP Inhibitors market due to several key factors. The region boasts advanced healthcare infrastructure, particularly in the United States and Canada, fostering rapid development and adoption of PARP inhibitors and companion diagnostics. High incidence rates of cancers such as breast and ovarian cancer drive demand for effective therapies like PARP inhibitors, supported by early adoption of innovative treatments facilitated by robust regulatory approvals from agencies like the FDA. North America's competitive pharmaceutical environment, featuring major players like AstraZeneca, Pfizer, and Merck with extensive PARP inhibitor portfolios, fuels continuous innovation and market expansion. The integration of genomic testing in oncology practices further enhances treatment precision, enabling targeted PARP inhibitor therapy based on biomarkers such as BRCA mutations.


Recent Developments:

  • In August 2022, Artios Pharma Limited has launched a Phase 2 study for ART4215, a small molecule inhibitor targeting polymerase theta (Polθ), in combination with talazoparib (TALZENNA®), an oral PARP inhibitor. This expansion study specifically aims to treat BRCA deficient breast cancer patients.
  • In Feb 2023, Pfizer announced positive Phase 3 results from the TALAPRO-2 study of TALZENNA® (talazoparib) combined with XTANDI® (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC), showing a significant improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI. The FDA has granted Priority Review for Pfizer’s application to use TALZENNA in combination with XTANDI for treating men with mCRPC.
  • In Sep 2022, Merck has partnered with Nerviano Medical Sciences S.r.l. (NMS) for NMS-293, a next-gen PARP1 inhibitor. NMS-293, highly selective and brain-penetrant, shows potential in combination with DNA-damaging agents and DNA response inhibitors across tumor types. It's in early clinical development for BRCA-mutated tumors and in combination with temozolomide for recurrent glioblastoma.


Segmentation of PARP Inhibitors Market-

By Product:

  • Niraparib (Zejula)
  • Olaparib (Lynparza)
  • Rucaparib (Rubraca)
  • Talazoparib (Talzenna)
  • Veliparib
  • Other Pipeline Drugs

By Indication:

  • Ovarian Cancer
  • Breast cancer
  • Prostate and Pancreatic Cancer


By Region-

North America-

  • The US
  • Canada
  • Mexico


  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe


  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa